Form 4: Foghorn Therapeutics Executive Granted Stock Options

Carlos Costa, Chief People Officer at Foghorn Therapeutics, was granted 115,000 stock options on January 22, 2025.

Summary

• Carlos Costa, the Chief People Officer of Foghorn Therapeutics, received 115,000 stock options on January 22, 2025.
• The exercise price for these options is $4.37 per share.
• The options vest over time, with 25% vesting on January 22, 2026, and the remaining 75% vesting quarterly at a rate of 6.25% per quarter.
• The options expire on January 21, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech industry, similar to companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals.
• The vesting schedule is typical, with a cliff vesting period followed by quarterly vesting, which is consistent with industry norms.

Stakeholder Impact

• The stock option grant may positively impact shareholder value by incentivizing the executive to improve company performance.
• The grant has a positive impact on the executive's compensation.

Key Dates

Keywords

stock options, executive compensation, Foghorn Therapeutics, vesting, equity, FHTX, Carlos Costa